Drug Profile
M 012
Alternative Names: M-012Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator University of California at Los Angeles
- Developer Merganser Biotech
- Class Peptides
- Mechanism of Action Hepcidin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Iron overload